Precision BioSciences Q1 net loss $18.4M; cash $125.8M; PBGENE-HBV and PBGENE-DMD trials advancing

PRECISION BIOSCIENCES INC

2026-Q1 EPS reported -$0.75 revenue$10,838,000

Net loss $18.4M ($0.75/share) vs $20.6M loss ($2.21/share) in Q1 2025.
Revenue $10.8M (vs <$0.1M YoY) driven by $7.5M TG Therapeutics milestone payment for Azer-Cel.
Cash, equivalents, restricted cash $125.8M as of March 31; expected funding through 2028.
PBGENE-HBV: 16 patients treated across 5 cohorts; late-breaking poster accepted at EASL Congress May 27-30.
PBGENE-DMD: FDA IND clearance, Fast Track; first site (Arkansas Children's Hospital) activated, enrolling patients.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

PRECISION BIOSCIENCES INC reported financial results for first quarter ended March 31, 2026.

Period: first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.

View on SEC.gov

Browse all earnings releases →

PRECISION BIOSCIENCES INC filing history →

Source: SEC EDGAR

accession 0001628280-26-030123

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.